BTIG reiterates Buy rating and $178 target for Nektar Therapeutics
BTIG reiterated a Buy rating on Nektar Therapeutics and set a $178.00 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 212.0% from the Sep 25 close of $57.06.Key takeaways from the analyst noteStrong Clinical Data for REZPEG: Nektar Therapeutics has demonstrated a strong safety and ef…